ADIPOQ and obesity disorder: For adiponectin, those with the greatest increase (Tertile 3) showed a trend toward lower odds of obesity (OR 0.52, 95% CI 0.25–1.06), abdominal obesity (OR 0.46, 95% CI 0.20–1.02) and severe sarcopenia (OR 0.40, 95% CI 0.14–1.15) compared to Tertile 1; however, these associations were not statistically significant.